Refine Search

Search Results -

| Terms | Documents |
|------------------|-----------|
| L12 and L9 or L8 | 4 |

US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index

US Pre-Grant Publication Full-Text Database

IBM Technical Disclosure Bulletins

Search:

| 13 | | | Refine Search |
|----|---------------|-------|---------------|
| | Recall Text 🗢 | Clear | Interrupt |

Search History

DATE: Friday, April 01, 2005 Printable Copy Create Case

| Set Name side by side | Query | <u>Hit</u> Count | <u>Set</u> <u>Name</u> result set |
|-----------------------|--|---------------------|---|
| DB=P | PGPB, USPT, USOC, EPAB, JPAB, DWPI; PLUR=YES; OP=ADJ | | |
| <u>L13</u> | L12 and L9 or L8 | 4 | <u>L13</u> |
| <u>L12</u> | L5 or L6 or L7 | 629 | <u>L12</u> |
| <u>L11</u> | L5 and L6 | 0 | <u>L11</u> |
| <u>L10</u> | L4 and enhancing clot dissolution | 7 | <u>L10</u> |
| <u>L9</u> | L4 and reducing reocclusion | 5 | <u>L9</u> |
| <u>L8</u> | L4 and enhancing reperfusion | 4 | <u>L8</u> |
| <u>L7</u> | L4 and thrombotic disorder | 610 | <u>L7</u> |
| <u>L6</u> | L4 and enhancing clot formation | 18 | <u>L6</u> |
| <u>L5</u> | L4 and slowing clot formation | 7 | <u>L5</u> |
| <u>L4</u> | L3 and (therapeut\$\$\$ or treat\$\$\$ or prevent\$\$\$ or enhanc\$\$\$ or administe\$\$\$ or increas\$\$\$) | 14506 | <u>L4</u> |
| <u>L3</u> | L2 and (coagulat\$\$\$ or repurfus\$\$\$ or reocclus\$\$\$) | 15253 | <u>L3</u> |
| <u>L2</u> | L1 and thrombolytic or anticoagulant or thrombotic or clot | 54101 | <u>L2</u> |

<u>L1</u> Bacterial permeability protein or BPI

3882 <u>L1</u>

END OF SEARCH HISTORY

Generate Collection

Print

Search Results - Record(s) 1 through 4 of 4 returned.

- 1. 5935930. 20 Apr 98; 10 Aug 99. Antithrombotic materials and methods. White; Mark L., et al. 514/12: 424/529 424/532 514/21 514/822 530/324 530/350 530/829. A61K038/00 A61K038/16.
- 2. 5510330. 25 Mar 94; 23 Apr 96. Combinations of thrombolytically active proteins and nonheparin anticoagulants, and uses thereof.. Martin; Ulrich, et al. 514/12; 424/94.63 424/94.64 435/212 435/215 435/216 435/226. A61K038/00 A61K038/48.
- 3. <u>US 5741779A</u>. Use of bactericidal/permeability-increasing protein products for slowing clot formation and enhancing clot dissolution in blood, particularly for treating thrombotic disorders. AMMONS, W.S. et al. A61K038/00 A61K038/16 A61K038/17 A61K038/36 A61K038/49 A61P007/02 A61P009/00 C07K014/435 C07K014/47 A61K038/49 A61K038:17 A61K038/49 A61K038:17 A61P007:02 A61K038/49 A61K038:17.
- 4. EP 751785B. Pharmaceutical combination providing bolus treatment for thrombotic disease uses non-heparin anticoagulant e.g. hirudin or hirulog, and protein active thrombolytically e.g. plasminogen activator, FISCHER, S, et al. A61K000/00 A61K009/08 A61K031/725 A61K037/000 A61K038/00 A61K038/36 A61K038/43 A61K038/46 A61K038/48 A61K038/49 A61K038/55 A61K038/58 A61K031:725 A61K038/58 A61K038:48 A61K031:725 A61K038/58 A61K038:48 A61K031:725 A61K038/58 A61K038:48 A61K031:725 A61K038/58 A61K038:48 A61K031:725 A61K038/58 A61K038:48.

Generate Collection Print

| Terms | Documents |
|------------------|-----------|
| L12 and L9 or L8 | 4 |

Prev Page Next Page Go to Doc# Generate Collection

Print

Search Results - Record(s) 1 through 5 of 5 returned.

- 1. 20040235792. 18 Dec 03. 25 Nov 04. Serine protease inhibitors compromising a hydrogen-bond acceptor. Deadman, John J, et al. 514/64; 558/287 A61K031/69 C07F005/04.
- 2. <u>5935930</u>. 20 Apr 98; 10 Aug 99. Antithrombotic materials and methods. White; Mark L., et al. 514/12: 424/529 424/532 514/21 514/822 530/324 530/350 530/829. A61K038/00 A61K038/16.
- 3. <u>5510330</u>. 25 Mar 94; 23 Apr 96. Combinations of thrombolytically active proteins and nonheparin anticoagulants, and uses thereof.. Martin; Ulrich, et al. 514/12; 424/94.63 424/94.64 435/212 435/215 435/216 435/226, A61K038/00 A61K038/48.
- 4. <u>US 5741779A</u>. Use of bactericidal/permeability-increasing protein products for slowing clot formation and enhancing clot dissolution in blood, particularly for treating thrombotic disorders. AMMONS, W S, et al. A61K038/00 A61K038/16 A61K038/17 A61K038/36 A61K038/49 A61P007/02 A61P009/00 C07K014/435 C07K014/47 A61K038/49 A61K038:17 A61K038/49 A61K038:17 A61P007:02 A61K038/49 A61K038:17.
- 5. WO 9006134A. Novel human platelet-specific antibodies useful in anti-thrombotic therapy and for scintigraphic imaging of thrombi. COLLER, B S, et al. A61K039/39 A61K049/02 C12N005/22 C12P021/08.

Generate Collection Print

Terms Documents L4 and reducing reocclusion

> Prev Page Next Page Go to Doc#

Generate Collection

Print

Search Results - Record(s) 1 through 7 of 7 returned.

- 1. 6599881. 06 Jul 00; 29 Jul 03. Antithrombotic materials and methods. White; Mark L., et al. 514/12; 424/529 424/532 514/21 514/822 530/324 530/350 530/829. A61K038/00 A61K038/16.
- 2. <u>6107280</u>. 26 Apr 99; 22 Aug 00. Antithrombotic materials and methods. White; Mark L., et al. 514/12; 424/529 424/532 514/21 514/822 530/324 530/350 530/829. A61K038/00 A61K038/16.
- 3. <u>5935930</u>. 20 Apr 98; 10 Aug 99. Antithrombotic materials and methods. White; Mark L., et al. 514/12; 424/529 424/532 514/21 514/822 530/324 530/350 530/829. A61K038/00 A61K038/16.
- ₩ 4. <u>5741779</u>. 10 May 96; 21 Apr 98. Antithrombotic materials and methods. White; Mark L., et al. 514/12; 514/822 530/324. A61K038/16 A61K038/17 A61K038/36 C07K014/435.
- 5. <u>5474531</u>. 01 Nov 94; 12 Dec 95. Apparatus and method for <u>enhanced</u> intravascular phonophoresis including dissolution of intravascular blockage and concomitant inhibition of restenosis. Carter; Robert E.. 604/22; 606/128. A61B017/22.
- 6. <u>5362309</u>. 10 May 93; 08 Nov 94. Apparatus and method for <u>enhanced</u> intravascular phonophoresis including dissolution of intravascular blockage and concomitant inhibition of restenosis. Carter; Robert E.. 604/22; 606/128. A61B017/32.
- 7. <u>US 5741779A</u>. Use of bactericidal/permeability-increasing protein products for slowing clot formation and enhancing clot dissolution in blood, particularly for treating thrombotic disorders. AMMONS, W S, et al. A61K038/00 A61K038/16 A61K038/17 A61K038/36 A61K038/49 A61P007/02 A61P009/00 C07K014/435 C07K014/47 A61K038/49 A61K038:17 A61K038/49 A61K038:17 A61P007:02 A61K038/49 A61K038:17.

Generate Collection Print

| Terms | Documents |
|-----------------------------------|-----------|
| L4 and enhancing clot dissolution | 7 |

Prev Page Next Page Go to Doc#